Document is current
Any future updates will be listed below
-
Authors
Turan, Leyla
Arnold-Vangsted, Andreas
la Cour, Morten
Hodzic-Hadzibegovic, Delila
Hajari, Javad N.
Klefter, Oliver N.
Schneider, Miklos
Subhi, Yousif https://orcid.org/0000-0001-6620-5365
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 15 January 2025
First Online: 3 February 2025
Declarations
:
: Leyla Turan, Andreas Arnold-Vangsted, Morten la Cour, Javad Nouri Hajari, and Oliver Niels Klefter declare that they have no competing interests. Delila Hodzic-Hadzibegovic declares to have served as an advisory board member for Roche. Miklos Schneider declares to have served as an advisory board member for Novartis and Roche and Bayer, to have acted as a consultant for AbbVie, received speaker fees from AbbVie and Roche, and received travel grants from AbbVie, Bayer and Roche, not related to this work. Yousif Subhi declares to have received speakers fee from Bayer and Roche, and to be the inventor of a patent related to the use of biomarkers of polypoidal choroidal vasculopathy (WO2020007612A1), not related to this work. Yousif Subhi is Section Editor of Ophthalmology and Therapy. Yousif Subhi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: We obtained permission for this database study from the Local Department Research Committee (jr. nr. 6-FSU-2023-13) and the Regional Data Protection Agency (jr. no.: R-20052134). Further approvals were not required due to the retrospective nature of the study. All aspects of this study adhered to the Declaration of Helsinki and its later amendments.
